Akèy › Leksemi biphenotipik egi › Texas

Etid klinik pou Leksemi biphenotipik egi nan Texas

13 etid pou Leksemi biphenotipik egi ap chèche patisipan nan sit nan Texas.

Vil nan Texas

Tèks ofisyèl etid la (Anglè)

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

University of Texas MD Anderson Cancer Center, Houston

Ap rekriteFaz 1

Laj 12 a 78 · Tout sèks · Mizajou Sep 29, 2026 · NCT03802695

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Dell Children's Medical Center of Central Texas, Austin
Driscoll Children's Hospital, Corpus Christi
Medical City Dallas Hospital, Dallas
ak 7 plis

Ap rekriteFaz 2

365 Days · Tout sèks · Mizajou Sep 25, 2026 · NCT06317662

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

M D Anderson Cancer Center, Houston

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT03683433

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Dell Children's Medical Center of Central Texas, Austin
Driscoll Children's Hospital, Corpus Christi
Medical City Dallas Hospital, Dallas
ak 12 plis

Ap rekriteFaz 3

365 Days – 25 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT03959085

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Dell Children's Medical Center of Central Texas, Austin
Driscoll Children's Hospital, Corpus Christi
Medical City Dallas Hospital, Dallas
ak 10 plis

Ap rekriteFaz 1/2

Jiska laj 22 · Tout sèks · Mizajou Aug 25, 2026 · NCT04726241

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

University of Texas MD Anderson Cancer Center, Houston

Ap rekriteFaz 1/2

Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

UT Southwestern/Simmons Cancer Center, Dallas
Cook Children's Medical Center, Fort Worth

Ap rekriteFaz 1

Laj 1 a 30 · Tout sèks · Mizajou Aug 3, 2026 · NCT06177067

Personalized NK Cell Therapy in CBT

M D Anderson Cancer Center, Houston

Ap rekriteFaz 2

Laj 15 a 80 · Tout sèks · Mizajou Jul 30, 2026 · NCT02727803

A Study of Revumenib and Mezigdomide in People With Leukemia

MD Anderson Cancer Center (Data Collection Only), Houston

Ap rekriteFaz 1/2

Laj 12 ak plis · Tout sèks · Mizajou Jun 22, 2026 · NCT07356154

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M D Anderson Cancer Center, Houston

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Jun 12, 2026 · NCT04047641

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

M D Anderson Cancer Center, Houston

Ap rekriteFaz 2

Laj 18 a 65 · Tout sèks · Mizajou May 20, 2026 · NCT02115295

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

University of Texas(UT) Southwestern-Children's Medical Center, Dallas

Ap rekriteFaz 1/2

Laj 12 a 95 · Tout sèks · Mizajou Apr 15, 2026 · NCT04329728

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

University of Texas, Southwestern, Dallas
Cook Children's Hospital, Fort Worth
Texas Children's Hospital/Baylor College of Medicine, Houston

Ap rekriteFaz 1

Laj 1 a 21 · Tout sèks · Mizajou Dec 6, 2024 · NCT05476770

Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.